<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The febrile neonate (28 days of age or younger): Outpatient evaluation and initial management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The febrile neonate (28 days of age or younger): Outpatient evaluation and initial management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">The febrile neonate (28 days of age or younger): Outpatient evaluation and initial management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hannah F Smitherman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles G Macias, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen J Teach, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James F Wiley, II, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1978032247"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The outpatient evaluation of febrile neonates (≤28 days old) is discussed in this topic.</p><p>For a discussion of the management of febrile infants 29 to 90 days old; the definition of fever in the young infant; the diagnosis, evaluation, and initial management of neonatal sepsis, and the approach to the ill-appearing infant without fever, refer to the following topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/106744.html" rel="external">"The febrile infant (29 to 90 days of age): Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6073.html" rel="external">"The febrile infant (younger than 90 days of age): Definition of fever"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a> and  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)"</a>.)</p><p></p><p class="headingAnchor" id="H454914468"><span class="h1">TERMINOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever</strong> – We define fever in neonates as a rectal temperature of ≥38°C (100.4°F). This is the standard for detecting fever in neonates because most studies establishing the risk of serious infections in neonates have relied upon rectal temperatures. (See  <a class="medical medical_review" href="/d/html/6073.html" rel="external">"The febrile infant (younger than 90 days of age): Definition of fever", section on 'Definition of fever'</a>.)</p><p></p><p class="bulletIndent1">Interpretation of other means of temperature measurement and caregiver reports of fever in young infants is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6073.html" rel="external">"The febrile infant (younger than 90 days of age): Definition of fever", section on 'Definition of fever'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Invasive bacterial infection (IBI)</strong> –<strong> </strong>For this topic, IBI refers to bacteremia or meningitis. IBI supplants the previously used term "serious bacterial infection" (SBI), which includes urinary tract infection (UTI).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal sepsis</strong> – Febrile neonates with a positive blood culture for a bacterial pathogen meet criteria for neonatal sepsis. Sepsis is further defined by the infant's age at the onset of symptoms (see  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Terminology'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early-onset sepsis</strong> is defined either as the onset of symptoms before 72 hours of age or infections with onset at &lt;7 days of life.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Late-onset sepsis</strong> is often defined as the onset of symptoms at ≥72 hours of age. Like early-onset sepsis, there is variability in the definition, ranging from an onset at &gt;72 hours of life to ≥7 days of age.</p><p></p><p class="headingAnchor" id="H1462614342"><span class="h1">ETIOLOGY</span></p><p class="headingAnchor" id="H1911270287"><span class="h2">Viral infection</span><span class="headingEndMark"> — </span>Viral infection is a common cause of fever in neonates undergoing outpatient evaluation [<a href="#rid1">1-4</a>]. However, neonates with viral infection remain at high risk for concomitant invasive bacterial infection (IBI). Viruses that can cause serious illness in febrile neonates include:</p><p class="bulletIndent1"><span class="glyph">●</span>Herpes simplex virus (HSV) (see  <a class="medical medical_review" href="/d/html/6037.html" rel="external">"Neonatal herpes simplex virus infection: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Varicella-zoster virus (see  <a class="medical medical_review" href="/d/html/4969.html" rel="external">"Varicella-zoster infection in the newborn"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some enteroviruses (see  <a class="medical medical_review" href="/d/html/2693.html" rel="external">"Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Influenza virus (see  <a class="medical medical_review" href="/d/html/5973.html" rel="external">"Seasonal influenza in children: Clinical features and diagnosis", section on 'Clinical features'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some adenoviruses (see  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory syncytial virus (RSV) (see  <a class="medical medical_review" href="/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (see  <a class="medical medical_review" href="/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children", section on 'In infants &lt;12 months of age'</a>)</p><p></p><p>The neonate acquires viral infection through vertical transmission from the mother during delivery and postnatally from sources such as hospital personnel, family members, and daycare staff or attendees. Neonates are more likely than older infants to experience morbidity from a viral infection, in part because of a decreased responsiveness of T cell-mediated immunity. (See  <a class="medical medical_review" href="/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p class="headingAnchor" id="H1199501556"><span class="h2">Invasive bacterial infection</span></p><p class="headingAnchor" id="H2058509860"><span class="h3">Risk factors for IBI</span><span class="headingEndMark"> — </span>Risk factors for IBI in neonates undergoing outpatient evaluation include  (<a class="graphic graphic_table graphicRef134341" href="/d/graphic/134341.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – Traditionally, 28 days of age has been used as the threshold for a full sepsis evaluation in neonates with fever [<a href="#rid5">5-9</a>]. More recent evidence from large observational studies indicate that the highest risk for IBI occurs in febrile neonates ≤21 days old (bacteremia 3 to 5 percent, meningitis 1.1 to 2.7 percent) [<a href="#rid10">10,11</a>]. However, the risk for IBI in neonates 22 to 28 days old is still substantial [<a href="#rid11">11</a>]. Febrile neonates evaluated in primary care offices have rates of bacteremia and meningitis of 3 and 1.1 percent, respectively [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ill appearance</strong> – Ill appearance, including lethargy, irritability, respiratory distress, or poor perfusion, significantly increases the risk of IBI in febrile neonates undergoing outpatient evaluation [<a href="#rid12">12-14</a>]. However, signs of IBI may be subtle and difficult to identify.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prematurity (gestational age younger than 37 weeks)</strong> – Because of their immature immune protective mechanisms, premature infants are at a much higher risk for IBI. For example, premature infants have rates of sepsis that are approximately 10 to 12 times that of term infants, including late-onset sepsis. Thus, neonates who are premature should be regarded as being at increased risk for IBI. (See  <a class="medical medical_review" href="/d/html/88740.html" rel="external">"Clinical features and diagnosis of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Incidence'</a> and  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal group B </strong><strong><em>Streptococcus</em></strong><strong> (GBS) infection </strong>– Potential findings that increase the risk for early-onset sepsis in neonates &lt;14 days old include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maternal fever</p><p class="bulletIndent2"><span class="glyph">•</span>Chorioamnionitis typically caused by prolonged rupture of membranes</p><p class="bulletIndent2"><span class="glyph">•</span>Maternal colonization with GBS</p><p></p><p class="bulletIndent1">GBS screening and maternal intrapartum antibiotic prophylaxis reduce the risk of early-onset GBS infection but do not eliminate it. (See  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Maternal risk factors'</a> and  <a class="medical medical_review" href="/d/html/438.html" rel="external">"Prevention of early-onset group B streptococcal disease in neonates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbidities or chronic illness</strong> – Historically, studies of IBI in young infants have excluded patients with the following comorbidities who are considered at higher risk for IBI [<a href="#rid5">5,11</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants with a perinatal course that is complicated by surgery, infection, or congenital or chromosomal abnormalities</p><p class="bulletIndent2"><span class="glyph">•</span>Medically fragile patients who are dependent upon technology or specific therapies (eg, home ventilator, home oxygen, or total parenteral nutrition)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Received antibiotics within the prior three to</strong> <strong>seven days </strong>–<strong> </strong>Because of the long half-lives of antibiotics in neonates, administration from three up to seven days prior to evaluation may mask signs and symptoms of IBI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Social barriers to follow-up</strong> – Although it has not been shown to be a direct risk factor for IBI, factors that negatively impact the ability to re-evaluate a young febrile infant on an outpatient basis pose a risk for safe management:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Limited skills by the caregiver to assess severity of diseases/educational barriers</p><p class="bulletIndent2"><span class="glyph">•</span>Limited access to a medical home for questions and/or follow-up</p><p class="bulletIndent2"><span class="glyph">•</span>Lack of transportation</p><p class="bulletIndent2"><span class="glyph">•</span>Language and other communication limitations</p><p></p><p class="headingAnchor" id="H862322401"><span class="h3">Infection source and common pathogens</span><span class="headingEndMark"> — </span>Urinary tract infection (UTI) accounts for most bacterial infections in neonates undergoing outpatient evaluation for fever [<a href="#rid6">6,9,14</a>]. Bacteremia, cellulitis, meningitis, pneumonia, and osteomyelitis constitute other important but less common infection sources.</p><p><em>Escherichia coli </em>is the most common pathogen causing bacteremia (neonatal sepsis) and bacterial meningitis in febrile neonates presenting for outpatient evaluation, followed by GBS [<a href="#rid11">11,15-18</a>]<em>. E. coli</em> also causes the majority of UTIs in this age group. Other bacterial pathogens include [<a href="#rid19">19-21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>Staphylococcus</em> <em>aureus</em>, including community-acquired methicillin-resistant <em>S</em>. <em>aureus</em> (MRSA), usually association with skin, bone, or joint sites of involvement</p><p class="bulletIndent1"><span class="glyph">●</span><em>Streptococcus pneumoniae</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>Enterococcus faecalis</em></p><p class="bulletIndent1"><span class="glyph">●</span>Gram-negative bacteria such as<em> Enterobacter cloacae</em>, <em>Moraxella catarrhalis</em>, <em>Klebsiella</em> species, and <em>Citrobacter</em> species</p><p class="bulletIndent1"><span class="glyph">●</span><em>Salmonella</em> species may also cause bacteremia in neonates with diarrhea [<a href="#rid22">22,23</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><em>Listeria monocytogenes</em> (sporadic cause of late-onset sepsis and meningitis) (see  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Epidemiology'</a>)</p><p></p><p class="headingAnchor" id="H1881437042"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The febrile neonate demonstrates few, if any, interpretable clues to the underlying cause of fever on physical examination despite evaluation by experienced clinicians or the use of an observation scale score [<a href="#rid11">11,24,25</a>]. The risk of sepsis and invasive bacterial infection (IBI) remains elevated for all neonates, especially those ≤21 days old [<a href="#rid11">11</a>]. Furthermore, fever may be the only manifestation of late-onset sepsis prior to decompensation. It should be noted that approximately 50 percent of infants presenting with neonatal sepsis are normothermic or hypothermic. (See  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a>.)</p><p class="headingAnchor" id="H2143150248"><span class="h2">Stabilization</span><span class="headingEndMark"> — </span>Unstable neonates who have respiratory or circulatory compromise (eg, apnea, respiratory distress, or signs of shock [eg, tachycardia with poor perfusion]) must be quickly identified and treated  (<a class="graphic graphic_table graphicRef51456" href="/d/graphic/51456.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef128375" href="/d/graphic/128375.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)", section on 'Initial stabilization'</a>.)</p><p>These ill-appearing patients are at high risk for IBI and warrant a complete evaluation for sepsis  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a>) and prompt administration of empiric antibiotics. (See  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates"</a>.)</p><p>In addition to respiratory or circulatory compromise, ill-appearing infants may display irritability, poor tone, or lethargy. A careful physical examination may identify a pattern of clinical features that suggests the etiology of an infant's symptoms and warrants further studies in addition to a sepsis evaluation. (See  <a class="medical medical_review" href="/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H1779217389"><span class="h2">History</span><span class="headingEndMark"> — </span>For the febrile neonate, history should focus on identifying risk factors for IBI and on subtle signs and symptoms of illness, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Poor feeding (eg, decreased frequency, amount, or length of feeding; and, for breastfeeding infants, weak sucking)</p><p class="bulletIndent1"><span class="glyph">●</span>Lethargy (eg, increased sleeping or difficulty waking the infant)</p><p class="bulletIndent1"><span class="glyph">●</span>Increased crying</p><p class="bulletIndent1"><span class="glyph">●</span>Weak cry</p><p class="bulletIndent1"><span class="glyph">●</span>Difficulty breathing</p><p></p><p>For neonates in whom fever is the only presenting symptom reported by caregivers, the clinician should determine how the temperature was taken and the exact reading. Rectal temperatures are the standard for detecting fever in neonates. (See  <a class="medical medical_review" href="/d/html/6073.html" rel="external">"The febrile infant (younger than 90 days of age): Definition of fever", section on 'Definition of fever'</a>.)</p><p>Perinatal history should identify maternal risk factors that indicate a higher risk for late-onset neonatal sepsis or herpes simplex virus (HSV) infection:</p><p class="bulletIndent1"><span class="glyph">●</span>Late-onset sepsis (most applicable to neonates &lt;14 days old) (see  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Maternal risk factors'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maternal fever</p><p class="bulletIndent2"><span class="glyph">•</span>Maternal colonization with group B <em>Streptococcus</em> (GBS) and/or administration of antibiotic prophylaxis at delivery</p><p class="bulletIndent2"><span class="glyph">•</span>Chorioamnionitis typically caused by prolonged rupture of membranes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HSV infection (applicable to all neonates) (see  <a class="medical medical_review" href="/d/html/6037.html" rel="external">"Neonatal herpes simplex virus infection: Clinical features and diagnosis", section on 'Epidemiology and transmission'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active genital lesions at the time of delivery</p><p class="bulletIndent2"><span class="glyph">•</span>Maternal history of sexually transmitted infections (STIs) such as HSV, gonorrhea, and chlamydia</p><p></p><p>Neonates with the following risk factors also remain at significant risk of IBI and sepsis:</p><p class="bulletIndent1"><span class="glyph">●</span>History of prematurity (gestational age younger than 37 weeks)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comorbidities or chronic illness, including infants whose perinatal course was complicated by surgery, infection, or congenital or chromosomal anomalies; or those who are medically fragile (eg, receiving home ventilator therapy, home oxygen, or total parenteral nutrition)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotic administration in the past seven days due to potential masking of a partially treated IBI</p><p></p><p class="headingAnchor" id="H3486415036"><span class="h2">Physical examination</span></p><p class="headingAnchor" id="H3206124160"><span class="h3">Appearance</span><span class="headingEndMark"> — </span>Ill-appearing neonates require emergency stabilization, comprehensive sepsis evaluation  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a>), and treatment. (See <a class="local">'Ill-appearing'</a> below.)</p><p>For most neonates, comprehensive sepsis evaluation is required despite well appearance. However, selected neonates 22 to 28 days old may undergo a stepwise evaluation (see <a class="local">'22 to 28 days old'</a> below) [<a href="#rid11">11</a>]. Identifying a young infant as well-appearing relies heavily upon the clinician's pediatric knowledge and experience. Prior to the development of a social smile at approximately six weeks of age, this task is especially challenging.</p><p>In addition to a careful physical examination, determination that a neonate is well requires observation over time to ensure that the infant feeds well, remains vigorous, maintains normal vital signs, and does not develop new findings suggestive of bacterial illness (eg, tachypnea, tachycardia, pulmonary rales, focal bone or joint tenderness, abdominal tenderness, petechiae, or purpura).</p><p class="headingAnchor" id="H199986236"><span class="h3">Degree of fever</span><span class="headingEndMark"> — </span>For most neonates, the height of the fever does not change further evaluation or management.</p><p>However, for well-appearing neonates 22 to 28 days old with rectal temperatures ≥38°C (100.4°F) and no obvious source of infection on physical examination, the likelihood of IBI (bacteremia or meningitis) and urinary tract infection (UTI) increases with higher fevers. A rectal temperature &gt;38.5°C (101.3°F) is the recommended threshold for performing more comprehensive evaluation for IBI in these patients [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3036211564"><span class="h3">Signs of focal infection</span><span class="headingEndMark"> — </span>During physical examination, the clinician should look for focal infection as indicated by the following signs:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focal bacterial infections</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute suppurative otitis media</strong> – Bulging and inflammation of the tympanic membrane  (<a class="graphic graphic_picture graphicRef63268" href="/d/graphic/63268.html" rel="external">picture 1</a>) or perforation of the tympanic membrane with acute purulent otorrhea (rare in neonates) (see  <a class="medical medical_review" href="/d/html/6009.html" rel="external">"Acute otitis media in children: Clinical manifestations and diagnosis", section on 'Otoscopic evaluation'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pneumonia</strong> – Tachypnea, respiratory distress (including grunting, flaring, and retractions), decreased oxygen saturation, cough, crackles, or decreased breath sounds on auscultation (see  <a class="medical medical_review" href="/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Clinical evaluation'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Omphalitis</strong> – Purulent drainage from the umbilical stump, circumferential erythema with tenderness and/or induration around the umbilicus  (<a class="graphic graphic_picture graphicRef63960" href="/d/graphic/63960.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef71634" href="/d/graphic/71634.html" rel="external">picture 3</a>), and/or foul odor (see  <a class="medical medical_review" href="/d/html/5009.html" rel="external">"Care of the umbilicus and management of umbilical disorders", section on 'Omphalitis'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bacterial arthritis</strong> – Swollen, painful, warm, and/or red joint with decreased range of motion  (<a class="graphic graphic_picture graphicRef88934 graphicRef89224" href="/d/graphic/88934.html" rel="external">picture 4A-B</a>) (see  <a class="medical medical_review" href="/d/html/6030.html" rel="external">"Bacterial arthritis: Clinical features and diagnosis in infants and children", section on 'Neonates and infants'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Osteomyelitis</strong> – Decreased movement of a limb with localized swelling or erythema (see  <a class="medical medical_review" href="/d/html/6064.html" rel="external">"Hematogenous osteomyelitis in children: Clinical features and complications", section on 'Birth to three months'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cutaneous cellulitis or abscess</strong> – Redness, induration, warmth, and drainage from a skin lesion, which is often located in the scalp at the site of monitoring probe insertion</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mastitis</strong> – Unilateral breast redness, tenderness, and induration that may have fluctuance or purulent nipple discharge (see  <a class="medical medical_review" href="/d/html/5974.html" rel="external">"Mastitis and breast abscess in infants younger than two months"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Meningitis</strong> – Irritability, lethargy, decreased or increased tone on examination, bulging fontanelle (late finding), and nuchal rigidity (rare finding in neonates) (see  <a class="medical medical_review" href="/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Clinical findings'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serious viral infections</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HSV infection</strong> – Clinical findings concerning for HSV infection include (see  <a class="medical medical_review" href="/d/html/6037.html" rel="external">"Neonatal herpes simplex virus infection: Clinical features and diagnosis", section on 'Clinical suspicion'</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Mucocutaneous vesicles  (<a class="graphic graphic_picture graphicRef56041" href="/d/graphic/56041.html" rel="external">picture 5</a> and <a class="graphic graphic_picture graphicRef78598" href="/d/graphic/78598.html" rel="external">picture 6</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Seizures, which typically consist of facial automatisms (eg, lip smacking or pursing), eye deviation, or unresponsiveness rather than tonic-clonic motor activity</p><p class="bulletIndent3"><span class="glyph">-</span>Focal neurologic signs</p><p class="bulletIndent3"><span class="glyph">-</span>Respiratory distress, apnea, or progressive pneumonitis</p><p class="bulletIndent3"><span class="glyph">-</span>Conjunctivitis, excessive tearing, or painful eye symptoms</p><p class="bulletIndent3"><span class="glyph">-</span>Sepsis-like illness (fever or hypothermia, irritability, lethargy, respiratory distress, apnea, abdominal distension, hepatomegaly, or ascites)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bronchiolitis</strong> – Tachypnea, copious nasal discharge, cough, auscultation demonstrating rales and/or wheezing, or apnea (see  <a class="medical medical_review" href="/d/html/6018.html" rel="external">"Bronchiolitis in infants and children: Clinical features and diagnosis", section on 'Clinical features'</a>)</p><p></p><p class="headingAnchor" id="H1114166352"><span class="h2">Ancillary studies</span></p><p class="headingAnchor" id="H4188530647"><span class="h3">Ill-appearing</span><span class="headingEndMark"> — </span>Regardless of age, young neonates who are ill appearing are at high risk for IBI and warrant a full evaluation for sepsis  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a>) [<a href="#rid9">9,24,26</a>].</p><p>In addition to diagnostic testing to identify IBI and UTI, diagnostic testing for viral etiologies may be warranted in selected patients:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>HSV</strong> – Infants with clinical suspicion for HSV infection  (<a class="graphic graphic_table graphicRef106132" href="/d/graphic/106132.html" rel="external">table 4</a>) warrant additional blood and cerebrospinal fluid (CSF) studies, surface viral cultures, and scraping from skin vesicles or mucous membranes for additional testing as described separately. (See  <a class="medical medical_review" href="/d/html/6037.html" rel="external">"Neonatal herpes simplex virus infection: Clinical features and diagnosis", section on 'Neonatal HSV'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory syncytial virus (RSV)</strong> – Ill-appearing infants with clinical findings of bronchiolitis warrant rapid testing for respiratory viruses (eg, RSV) to permit proper infection control measures during hospitalization. However, empiric antibiotics are still indicated. (See <a class="local">'Other viral infections'</a> below and  <a class="medical medical_review" href="/d/html/6018.html" rel="external">"Bronchiolitis in infants and children: Clinical features and diagnosis", section on 'Approach to testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza</strong> – During high seasonal prevalence, testing for influenza using highly accurate testing  (<a class="graphic graphic_table graphicRef69655" href="/d/graphic/69655.html" rel="external">table 5</a>) is helpful for determining the need for continued contact precautions and antiviral treatment in neonates. However, laboratory confirmation is <strong>not</strong> necessary before initiation of these measures and should not delay their initiation in patients in whom they are indicated. (See  <a class="medical medical_review" href="/d/html/5973.html" rel="external">"Seasonal influenza in children: Clinical features and diagnosis", section on 'Whom to test'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) </strong>– Coronavirus disease 2019 (COVID-19) can cause fever with or without ill appearance in young infants. Therefore, SARS-CoV-2 viral testing (nasal or nasopharyngeal swab for nucleic acid amplification testing [NAAT], which includes polymerase chain reaction [PCR] testing) is indicated for infection control and COVID-19-specific treatment in all hospitalized patients. (See  <a class="medical medical_review" href="/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children", section on 'In infants &lt;12 months of age'</a> and  <a class="medical medical_review" href="/d/html/128389.html" rel="external">"COVID-19: Management in children"</a>.)</p><p></p><p>Other causes of ill appearance in addition to sepsis include child abuse, congenital heart disease, congenital adrenal hyperplasia, inborn errors of metabolism, malrotation with volvulus, and a variety of other conditions discussed separately. Infants with clinical manifestations suggesting a diagnosis other than or in addition to serious infection warrant additional studies based upon specific findings as discussed separately. (See  <a class="medical medical_review" href="/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)", section on 'Targeted Evaluation'</a>.)</p><p class="headingAnchor" id="H2846506756"><span class="h3">Focal infection</span><span class="headingEndMark"> — </span>All febrile neonates with focal infections (eg, acute otitis media, cellulitis, abscess, mastitis, pneumonia, osteomyelitis, bacterial arthritis, or omphalitis) require a complete sepsis evaluation  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a>).</p><p>For well-appearing, afebrile neonates with acute otitis media, the appropriate evaluation prior to administration of empiric antibiotics is unclear, and clinical practice varies [<a href="#rid27">27</a>]. It is important to be certain that physical findings of acute otitis media (eg, bulging tympanic membrane  (<a class="graphic graphic_picture graphicRef63268" href="/d/graphic/63268.html" rel="external">picture 1</a>)) are present. For these patients, we suggest obtaining a blood culture before beginning empiric oral antibiotics. Although the absence of fever in such patients is reassuring, it does not completely exclude a systemic process. The decision to forego any evaluation in afebrile neonates prior to administering empiric antibiotics for acute otitis media should be made with caution. It is important to weigh the risk of masking an IBI and the difficult situation that will arise if the infant subsequently becomes febrile or ill appearing. (See  <a class="medical medical_review" href="/d/html/6009.html" rel="external">"Acute otitis media in children: Clinical manifestations and diagnosis", section on 'Tympanic membrane findings'</a>.)</p><p>In a multicenter, retrospective study of 1637 afebrile young infants with acute otitis media (including 100 neonates), none of the 278 patients with blood cultures had bacteremia (0 percent, 95% CI 0-1.4 percent), and none of the 102 infants with CSF cultures had meningitis (0 percent, 95% CI 0-3.6 percent) [<a href="#rid27">27</a>]. The diagnosis of acute otitis media was not routinely verified by subspecialist consultation or tympanocentesis. Two neonates with 30-day follow-up had an adverse event requiring hospitalization, but cultures of blood, urine, and CSF were negative in both patients.</p><p class="headingAnchor" id="H915901631"><span class="h3">Diagnosed with viral infections</span><span class="headingEndMark"> — </span>For febrile neonates diagnosed with a viral infection, including RSV bronchiolitis, influenza, COVID-19, or other respiratory viral infections (eg, human rhinovirus, adenovirus, non-SARS-CoV-2 coronavirus, parainfluenza, and/or human metapneumovirus), we recommend a full sepsis evaluation  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a>) for neonates ≤21 days old. We suggest it for neonates 22 to 28 days old. Neonates with a viral infection remain at substantial risk for an IBI that does not appear to differ from neonates with negative testing for viral infection [<a href="#rid4">4,5,28-30</a>]. For example, in a retrospective study of over 287 neonates who tested positive for respiratory viruses, up to 2.1 percent also had an IBI [<a href="#rid4">4</a>]. The risk of concomitant bacterial infection decreases with advancing age in neonates.</p><p>Testing panels for viral pathogens such as human rhinovirus, adenovirus, non-SARS-CoV-2 coronavirus, parainfluenza, and/or human metapneumovirus are not always readily available and may be cost prohibitive depending upon the setting.</p><p>Evidence regarding the risk of IBI in neonates with SARS-CoV-2 infection is limited [<a href="#rid31">31</a>]. All febrile young infants warrant testing for SARS-CoV-2 regardless of their exposure history as part of the initial evaluation. Furthermore, chest radiographs are strongly encouraged for patients who are positive for SARS-CoV-2, regardless of respiratory symptoms. For those who are well appearing but have positive radiographic findings, hospital admission is advised, especially if oxygen saturation is consistently &lt;95 percent on room air, work of breathing is increased, or feeding is poor. (See  <a class="medical medical_review" href="/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children", section on 'In infants &lt;12 months of age'</a> and  <a class="medical medical_review" href="/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children", section on 'Laboratory tests for SARS-CoV-2'</a>.)</p><p class="headingAnchor" id="H3452192042"><span class="h3">Well-appearing</span><span class="headingEndMark"> — </span>Age and risk factors for bacterial or HSV infection are the primary determinants for the evaluation of well-appearing febrile young neonates. The risk of IBI for otherwise low-risk, febrile neonates is highest in the first three weeks of life and then decreases in the fourth week [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H301121160"><span class="h4">&lt;8 days old</span><span class="headingEndMark"> — </span>The evaluation of neonates &lt;8 days old with possible early-onset sepsis, which includes individuals with fever, is discussed separately. (See  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a>.)</p><p class="headingAnchor" id="H857933794"><span class="h4">8 to 21 days old</span><span class="headingEndMark"> — </span>We recommend that all febrile neonates 8 to 21 days of age undergo a full evaluation for sepsis, including studies to detect HSV for neonates with risk factors or physical examination findings for this infection  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/6037.html" rel="external">"Neonatal herpes simplex virus infection: Clinical features and diagnosis", section on 'Clinical suspicion'</a>.)</p><p>These patients also warrant empiric antibiotics  (<a class="graphic graphic_table graphicRef102574" href="/d/graphic/102574.html" rel="external">table 6</a>) and hospital admission to a unit with nurses and ancillary staff experienced in caring for neonates. (See <a class="local">'Neonates 8 to 21 days old'</a> below and  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Symptomatic neonates'</a>.)</p><p>The 2021 American Academy of Pediatrics Clinical Practice Guideline (AAP CPG) provides an algorithm for the evaluation and management of well-appearing, 8- to 21-day-old febrile neonates  (<a class="graphic graphic_algorithm graphicRef132304" href="/d/graphic/132304.html" rel="external">algorithm 2</a>) [<a href="#rid11">11</a>]. Due to the low risk of UTI in patients with normal urine results, the AAP CPG recommends sending a urine culture (obtained by bladder catheterization or suprapubic aspiration [SPA]) only when the urinalysis is positive (leukocyte esterase present on dipstick, &gt;5 white blood cells (WBCs)/high-power field [centrifuged urine], or &gt;10 WBCs/mm<sup>3</sup> [uncentrifuged urine]) [<a href="#rid11">11</a>]. However, it is reasonable for clinicians to send a urine culture obtained by catheterization or SPA in all febrile neonates younger than 21 days old in settings with documented low rates of specimen contamination and with timely specimen processing because false positives are less likely in such settings. (See  <a class="medical medical_review" href="/d/html/6072.html" rel="external">"The febrile infant (29 to 90 days of age): Outpatient evaluation", section on 'Urine examination'</a>.)</p><p>Based upon observational studies performed in febrile neonates presenting to the emergency department or pediatric provider office, the estimated risk for bacterial infection in febrile, well-appearing neonates 0 to 21 days of age is high (bacteremia 3 to 5 percent, meningitis 1.1 to 2.7 percent) [<a href="#rid10">10,11</a>]. The risk for UTI is higher (16 to 28 percent) [<a href="#rid10">10,32</a>]. However, a full sepsis evaluation was not performed in all febrile neonates in these studies; patients who did not undergo testing were assumed to have negative cultures based upon follow-up. Thus, these estimates may be low and may not be precise or generalizable. Nevertheless, the benefit of early detection and treatment of bacterial meningitis or HSV meningoencephalitis outweighs the risks of lumbar puncture. In addition, the ability to rapidly test for enterovirus as the cause of pleocytosis permits earlier discontinuation of antibiotics and hospital discharge.</p><p class="headingAnchor" id="H9566195"><span class="h4">22 to 28 days old</span><span class="headingEndMark"> — </span>Neonates with risk factors for IBI  (<a class="graphic graphic_table graphicRef134341" href="/d/graphic/134341.html" rel="external">table 1</a>) warrant a full sepsis evaluation  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a>).</p><p>The 2021 AAP CPG provides an algorithm for the evaluation and management of well-appearing, low-risk 22- to 28-day-old febrile neonates  (<a class="graphic graphic_algorithm graphicRef132303" href="/d/graphic/132303.html" rel="external">algorithm 3</a>) [<a href="#rid11">11</a>]. Our approach to evaluation differs because we consider the height of fever or positive urine studies as risk factors that require a complete sepsis evaluation even if other inflammatory markers (procalcitonin, C-reactive protein, or absolute neutrophil count) are normal:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Temperature &gt;38.5°C (101.3°F)</strong> – For otherwise low-risk, well-appearing, febrile neonates 22 to 28 days old with a rectal temperature &gt;38.5°C, we suggest a full sepsis evaluation  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Temperature ≤38.5°C </strong>– For low-risk, well-appearing, febrile neonates 22 to 28 days old with a rectal temperature ≤38.5°C, we suggest a full sepsis evaluation. However, a stepwise evaluation is an acceptable option for patients with normal blood inflammatory markers  (<a class="graphic graphic_table graphicRef134365" href="/d/graphic/134365.html" rel="external">table 7</a>) [<a href="#rid11">11</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Full sepsis evaluation</strong> – Traditionally, a full sepsis evaluation has been recommended in all febrile neonates regardless of age because of the poor ability to identify patients with IBI based upon appearance and results of blood and urine studies. However, there is growing evidence that neonates 22 to 28 days of age have a lower risk of IBI when inflammatory markers and urine studies are normal and can be safely managed without CSF studies being performed during the initial evaluation as discussed below [<a href="#rid11">11</a>] (see <a class="local">'Neonates 22 to 28 days old'</a> below). For this reason, the decision to perform a lumbar puncture in well-appearing febrile infants in this age group should be made as a shared decision between the clinician and family with a mutual understanding of the risks and benefits and with consideration of the family's values and preferences.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stepwise evaluation</strong> – With a stepwise approach, CSF studies are not obtained unless one or more inflammatory markers is abnormal (eg, procalcitonin, C-reactive protein, or absolute neutrophil count  (<a class="graphic graphic_table graphicRef134333" href="/d/graphic/134333.html" rel="external">table 8</a>); rectal temperature &gt;38.5°C (101.3°F) is considered an abnormal inflammatory marker if procalcitonin is not rapidly available). If inflammatory markers and urine studies are normal, clinicians and parents or caregivers may elect <strong>not</strong> to perform a lumbar puncture. Evidence suggests that the risk of IBI (primarily bacteremia) in such patients is 0.2 to 0.7 percent, which means that interpretable CSF studies would have to be performed in approximately 140 to 500 patients to diagnose one case of meningitis [<a href="#rid14">14,33,34</a>]. For some experts, this risk is low enough to not routinely perform a lumbar puncture in neonates 22 to 28 days old as long as close observation in the hospital is ensured until blood culture results are final [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent2">Due to the lower risk of UTI in these patients, the 2021 AAP CPG recommends sending a urine culture (obtained by bladder catheterization or SPA) only when the urinalysis is positive (leukocyte esterase present on dipstick, &gt;5 WBCs/high-power field [centrifuged urine], or &gt;10 WBCs<sup>/</sup>mm<sup>3</sup> [uncentrifuged urine]) [<a href="#rid11">11</a>]. However, it is reasonable for clinicians to send a urine culture obtained by catheterization or SPA in all febrile neonates younger than 22 to 28 days old in settings with documented low rates of specimen contamination and with timely specimen processing as false positives are less likely in such settings. (See  <a class="medical medical_review" href="/d/html/6072.html" rel="external">"The febrile infant (29 to 90 days of age): Outpatient evaluation", section on 'Urine examination'</a>.)</p><p></p><p class="bulletIndent1">Independent analysis of prospective, observational studies from the United States and Europe and a national surveillance study from England suggests that the prevalence of bacteremia in well-appearing, low-risk febrile neonates 22 to 28 days old is approximately 2 to 3 percent [<a href="#rid11">11</a>]. Based upon large United States health care system registry studies, the prevalence of bacterial meningitis is much lower in these neonates (0.3 to 0.4 percent) [<a href="#rid32">32,35</a>]. Given the low prevalence of bacterial meningitis, it is reasonable for clinicians to omit lumbar puncture for patients with normal urine studies, normal inflammatory markers, and no risk factors for HSV infection [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urine dipstick or urinalysis abnormal</strong> – For low-risk, well-appearing febrile neonates 22 to 28 days of age whose preliminary urine studies are abnormal, we suggest CSF studies be obtained regardless of the results of inflammatory markers. Evidence from observational studies suggests that the risk of bacterial meningitis in all neonates with positive urine studies is approximately 1 to 2 percent although the risk appears to be highest in neonates &lt;21 days old [<a href="#rid36">36-38</a>]. </p><p></p><p class="bulletIndent1">Our approach differs from the AAP CPG. Although the AAP CPG recommends performing a lumbar puncture for patients with abnormal urine studies and one or more elevated inflammatory markers, it indicates lumbar puncture may or may not be performed if inflammatory markers are normal [<a href="#rid11">11</a>]. In other observational studies that have included well-appearing neonates 22 to 28 days of age, IBI has occurred in approximately 5 percent of all patients &gt;21 days old with abnormal urine dipstick results (positive leukocyte esterase and/or nitrites); however, bacteremia has accounted for almost all IBIs in these patients, and meningitis has been rare (&lt;1 percent) [<a href="#rid39">39,40</a>]. Based on these studies, the negative predictive value for IBI in patients with an abnormal urine dipstick but normal procalcitonin and C-reactive protein is 100 percent with the lower limit of the 95 percent confidence interval 97.3 to 97.5 percent. Nevertheless, given the difficulty in discerning well appearance in this age group, the lack of sensitive predictors of meningitis in neonates with UTIs, and the limited numbers of patients 22 to 28 days old included in these studies, we still suggest a full evaluation.</p><p></p><p class="headingAnchor" id="H1790856854"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Appearance, age, and (for neonates 22 to 28 days old who undergo stepwise evaluation) the results of initial ancillary studies determine management.</p><p class="headingAnchor" id="H3735866737"><span class="h2">Ill-appearing</span><span class="headingEndMark"> — </span>Regardless of age or degree of highest measured temperature, neonates who are ill appearing, have a weak cry, or have other abnormal behaviors are at higher risk of invasive bacterial infection (IBI) with sepsis and herpes simplex virus (HSV) [<a href="#rid9">9,26</a>]. In addition, neonates who are ill appearing but have normal or low temperature are also at significant risk for infection, as are those who are well-appearing with a low temperature.</p><p>Because over 10 percent of ill-appearing young infants may have IBIs [<a href="#rid14">14,24,41</a>], such infants should undergo the following treatment:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify and treat septic shock</strong> – Many ill-appearing infants have sepsis and require resuscitation according to the 2020 Surviving Sepsis Campaign international guidelines  (<a class="graphic graphic_algorithm graphicRef128375" href="/d/graphic/128375.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Rapid recognition'</a> and  <a class="medical medical_review" href="/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Resuscitation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify and treat other causes of ill appearance</strong> – Other causes of ill appearance in addition to sepsis include congenital heart disease, congenital adrenal hyperplasia, inborn errors of metabolism, malrotation with volvulus, or a variety of causes. Infants with clinical manifestations suggesting a diagnosis other than or in addition to serious infection warrant additional studies based upon specific findings as discussed separately. (See  <a class="medical medical_review" href="/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)", section on 'Targeted Evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ancillary studies</strong> – Ill-appearing neonates warrant a full evaluation for sepsis  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antimicrobial therapy</strong> – Empiric antimicrobial therapy using dosing for severe infections, meningitis, or septicemia should be given as soon as possible regardless of the initial laboratory results. Some ill-appearing infants may be too unstable from a respiratory or hemodynamic standpoint to undergo a lumbar puncture; in such cases, antimicrobial therapy should be given without delay.</p><p></p><p class="bulletIndent1">Empiric therapy in ill-appearing neonates  (<a class="graphic graphic_table graphicRef55679" href="/d/graphic/55679.html" rel="external">table 9</a>) (see  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates", section on 'Admitted from the community'</a> and  <a class="medical medical_review" href="/d/html/106447.html" rel="external">"Skin and soft tissue infections in neonates: Evaluation and management", section on 'Antimicrobial therapy'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">Ampicillin</a> <strong>and</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">Ceftazidime</a> <strong>or</strong> <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a> <strong>or</strong> <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a> (if available) <strong>or</strong> <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a> <strong>and</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">Acyclovir</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Add <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> for infants with septic shock or, in regions with a high prevalence (&gt;10 percent) of methicillin-resistant <em>S. aureus </em>(MRSA), suspicion of selected focal sites of infection outlined below or evidence of focal skin and soft tissue infection in the neonate or a household member (especially the mother)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospital admission</strong> – Ill-appearing febrile infants are at higher risk of decompensation and may have early or established septic shock that requires acute and ongoing resuscitation. They typically warrant admission to a pediatric-capable intensive care facility. (See  <a class="medical medical_review" href="/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Resuscitation'</a> and  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation"</a>.)</p><p></p><p class="headingAnchor" id="H1760792317"><span class="h2">Focal infection</span><span class="headingEndMark"> — </span>Febrile neonates with a focal infection require empiric parenteral antimicrobial therapy designed to cover perinatal pathogens and organisms commonly associated with the specific focal infection and hospitalization in a unit with nurses and staff experienced with caring for neonates. For those not familiar with the treatment of neonatal infections, consultation with a pediatric infectious disease specialist is encouraged.</p><p>Our suggested initial empiric regimens by type of focal infection are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abscess, cellulitis, osteomyelitis, or bacterial arthritis </strong>(see  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates", section on 'Coverage for focal sources of infection'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> and <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a> <strong>or</strong></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a>, <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a>, and <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a> (neonates with toxic appearance) <strong>or</strong></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> and an expanded-spectrum cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a>, <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a>, or, if available, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a>)</p><p></p><p class="bulletIndent1">Drainage and culture of any abscesses and, in ill-appearing infants with septic shock, surgical source control should accompany empiric antibiotic therapy. (See  <a class="medical medical_review" href="/d/html/6336.html" rel="external">"Techniques for skin abscess drainage"</a> and  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Eradicate infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Omphalitis</strong> (see  <a class="medical medical_review" href="/d/html/5009.html" rel="external">"Care of the umbilicus and management of umbilical disorders", section on 'Omphalitis'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">Vancomycin</a> <strong>and</strong></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">Gentamicin</a> <strong>or</strong>, in regions with substantial (&gt;10 percent) gentamicin-resistant <em>E. coli</em>, <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a>, <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a>, or, if available, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a></p><p class="bulletIndent2"><span class="glyph">•</span>In infants with foul-smelling umbilical discharge or those born to mothers with amnionitis, <strong>add</strong> <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> or <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> to cover anaerobic infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mastitis</strong> – Drainage of any concomitant abscess should accompany antibiotic treatment. Suggested regimens for infants with uncomplicated mastitis are provided in the table  (<a class="graphic graphic_table graphicRef111097" href="/d/graphic/111097.html" rel="external">table 10</a>). The clinician should tailor the empiric parenteral antibiotics to the prevalence of MRSA isolates in the community. Antimicrobial therapy for patients with severe complications (eg, extensive cellulitis, fasciitis, osteomyelitis, and/or shock) are discussed separately. (See  <a class="medical medical_review" href="/d/html/5974.html" rel="external">"Mastitis and breast abscess in infants younger than two months", section on 'Antimicrobial therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumonia </strong>–<strong> </strong>The treatment regimen is determined by age, clinical findings, and MRSA isolates in the community (see  <a class="medical medical_review" href="/d/html/5004.html" rel="external">"Neonatal pneumonia", section on 'Initial empiric therapy'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&lt;7 days old – <a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">Ampicillin</a> and <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a></p><p class="bulletIndent2"><span class="glyph">•</span>≥7 days old:</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">Ampicillin</a> <strong>or</strong>, in regions with high MRSA prevalence (generally considered to be &gt;10 percent of isolates), <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> <strong>plus</strong></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">Gentamicin</a> <strong>or</strong> an extended-spectrum cephalosporin (<a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a>, <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a>, or, if available, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a>)</p><p></p><p class="headingAnchor" id="H2528905554"><span class="h2">Well-appearing</span><span class="headingEndMark"> — </span>There is no consensus definition for what constitutes a "well-appearing" febrile neonate. The distinction between "well" and "ill" may not be clear cut, and an infant's appearance may change rapidly. Because of the difficulties in assessing well appearance, the clinical practice guideline with which this topic is in general accord should <strong>not</strong> be applied when clinicians are uncertain as to whether an infant is well appearing [<a href="#rid11">11</a>]. Furthermore, clinicians should adapt their approach if an infant's appearance deteriorates.</p><p class="headingAnchor" id="H1704141254"><span class="h3">Neonates &lt;8 days old</span><span class="headingEndMark"> — </span>The management of febrile neonates &lt;8 days old with sepsis, including neonates hospitalized since birth and those admitted from the community, is discussed separately. (See  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates"</a>.)</p><p class="headingAnchor" id="H2261866990"><span class="h3">Neonates 8 to 21 days old</span><span class="headingEndMark"> — </span>Well-appearing, febrile neonates ≤21 days old are at substantial risk for IBI and, after a comprehensive evaluation for sepsis, should receive empiric treatment with antimicrobial agents  (<a class="graphic graphic_table graphicRef55679" href="/d/graphic/55679.html" rel="external">table 9</a>) followed by admission to a hospital with nurses and staff experienced with caring for neonates  (<a class="graphic graphic_algorithm graphicRef132304" href="/d/graphic/132304.html" rel="external">algorithm 2</a>) [<a href="#rid11">11</a>]. (See <a class="local">'8 to 21 days old'</a> above.)</p><p>Empiric antimicrobial treatment is determined by preliminary findings of the evaluation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>No obvious source of infection </strong>– In neonates with no obvious source of infection suggested by initial evaluation, empiric antimicrobial regimens that provide coverage for <em>E. coli</em>, group B <em>Streptococcus</em> (GBS), <em>Enterococcus</em> species, <em>L. monocytogenes</em>, and other potential pathogens are indicated pending culture results (see  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates", section on 'Admitted from the community'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">Ampicillin</a> and <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a> <strong>or</strong></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">Ampicillin</a> and <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a> or <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a> (<a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a> if available)</p><p></p><p class="bulletIndent1">The combination of <a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">ampicillin</a> and <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a> or <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a> (<a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a> if available) is preferred in regions where there are high rates of gentamicin-resistant organisms, especially <em>E. coli</em> [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/6072.html" rel="external">"The febrile infant (29 to 90 days of age): Outpatient evaluation", section on 'Definition and risk factors'</a>.)</p><p></p><p class="bulletIndent1">Patients at risk due to exposure (maternal active genital lesions) should also undergo evaluation for HSV infection and receive <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a>  (<a class="graphic graphic_algorithm graphicRef106124" href="/d/graphic/106124.html" rel="external">algorithm 4</a>). (See  <a class="medical medical_review" href="/d/html/6040.html" rel="external">"Neonatal herpes simplex virus infection: Management and prevention", section on 'Initial antiviral therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected urinary tract infection (UTI)</strong> –<strong> </strong>The combination of parenteral <a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">ampicillin</a> and <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a> provides coverage for most common bacterial pathogens. However, with increasing reports of resistant organisms, local surveillance of pathogens and antibiotic susceptibility patterns may be important to determine appropriate initial antibiotic therapy. (See  <a class="medical medical_review" href="/d/html/4959.html" rel="external">"Urinary tract infections in neonates", section on 'Empiric therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal cerebrospinal fluid (CSF), traumatic tap, or dry tap</strong> – For neonates with CSF results that suggest bacterial meningitis  (<a class="graphic graphic_table graphicRef76324" href="/d/graphic/76324.html" rel="external">table 11</a>), treatment with <a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">ampicillin</a>, <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a>, and <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a> is warranted. Patients with CSF that is uninterpretable (traumatic or dry lumbar puncture) require the same antibiotic coverage. (See  <a class="medical medical_review" href="/d/html/6016.html" rel="external">"Bacterial meningitis in the neonate: Treatment and outcome"</a>.)</p><p></p><p class="bulletIndent1">CSF pleocytosis is also an indication for <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a> administration prior to virologic confirmation in otherwise well-appearing neonates. For neonates with a traumatic or dry tap, expert opinion differs. Regardless, if empiric acyclovir is given, then a comprehensive evaluation for HSV should be performed prior to acyclovir administration. (See  <a class="medical medical_review" href="/d/html/6040.html" rel="external">"Neonatal herpes simplex virus infection: Management and prevention", section on 'Initial antiviral therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focal infection </strong>– Empiric antibiotics are given according to the specific type of infection. (See <a class="local">'Focal infection'</a> above.)</p><p></p><p>While randomized trials evaluating antibiotic therapy in febrile neonates are lacking, the efficacy of this intervention is supported by the substantial reduction in sepsis-related infant mortality in the pre- and post-antibiotic eras [<a href="#rid42">42</a>]. Additional support comes from the observation that sepsis-related infant mortality is considerably lower in resource-rich regions where febrile neonates are routinely treated with antibiotics compared with resource-limited countries where timely access to antibiotic therapy may be limited [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H1645002632"><span class="h3">Neonates 22 to 28 days old</span><span class="headingEndMark"> — </span>Management of well-appearing neonates 22 to 28 days old has traditionally consisted of:</p><p class="bulletIndent1"><span class="glyph">●</span>Performing a full sepsis evaluation  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Administering empiric parenteral antibiotics  (<a class="graphic graphic_table graphicRef55679" href="/d/graphic/55679.html" rel="external">table 9</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Admitting the patient to the hospital</p><p></p><p>We prefer this traditional approach, and the 2021 American Academy of Pediatrics Clinical Practice Guideline (AAP CPG) acknowledges that this management is acceptable. However, the AAP CPG also suggests a modified evaluation in selected, well-appearing neonates 22 to 28 days old that uses the results of blood inflammatory markers and urine studies (urine dipstick and urinalysis) to make decisions about the need for lumbar puncture, urine culture, and further management  (<a class="graphic graphic_algorithm graphicRef132303" href="/d/graphic/132303.html" rel="external">algorithm 3</a>) [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal inflammatory markers with normal CSF and urine studies </strong>– According to the AAP CPG, all neonates 22 to 28 days old with any abnormal blood inflammatory marker  (<a class="graphic graphic_table graphicRef134333" href="/d/graphic/134333.html" rel="external">table 8</a>) should undergo lumbar puncture; urine culture is performed if urine studies are abnormal. For patients with normal CSF and urine results, reasonable alternatives to the traditional approach provided by the AAP CPG include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hospital observation without empiric antibiotics</strong> – For patients admitted to a hospital setting with nurses and ancillary staff experienced with managing neonates, empiric antimicrobials may be given although, per the AAP CPG, it is acceptable <strong>not</strong> to give antimicrobials pending blood, CSF, and (if obtained) urine culture results.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intramuscular (IM) </strong><a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a><strong> and home observation</strong> – Administration of an IM dose of ceftriaxone and discharge may occur <strong>only</strong> when the caregiver <strong>and</strong> clinician agree that:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The family has reliable phone and transportation to return if pending blood or CSF cultures become positive</p><p class="bulletIndent3"><span class="glyph">-</span>The caregiver is willing and able to observe the infant for deterioration</p><p class="bulletIndent3"><span class="glyph">-</span>Follow-up and administration of a second dose of IM <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a> within 24 hours of the first dose is ensured</p><p></p><p class="bulletIndent2">However, given the increased risk of IBI in neonates with any abnormal inflammatory marker, our preferred approach is for the patient to receive empiric antimicrobials and hospital admission. For patients who receive IM <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a> and discharge home, another consideration is that ceftriaxone alone is not adequate coverage for infection by <em>L. monocytogenes</em> or <em>Enterococcus</em> species.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal inflammatory markers and urine studies</strong> – According to the AAP CPG, neonates 22 to 28 days old with normal blood inflammatory markers and urinalysis may undergo a lumbar puncture, but the decision to perform a lumbar puncture should be made as a shared decision between the clinician and family with a mutual understanding of the risks and benefits and with consideration of the family’s values and preferences. Reasonable alternatives to the traditional approach include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lumbar puncture</strong> <strong>performed</strong> – Further management as determined by CSF results:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Normal CSF results</strong> – Hospital observation with or without empiric antibiotics <strong>or</strong> IM <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a> and home observation as described above for neonates 22 to 28 days old with abnormal blood inflammatory markers.</p><p></p><p class="bulletIndent3">Evidence suggests that the risk of IBI (primarily bacteremia) in such patients is very low (0.2 to 0.7 percent) [<a href="#rid11">11,14,33,34</a>]. Furthermore, clinical decompensation prior to the availability of blood and urine culture results during hospital observation appears to be rare [<a href="#rid10">10,14,33,39,44,45</a>]. Thus, clinicians may reasonably choose to withhold antibiotics while awaiting culture results.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Traumatic lumbar puncture</strong> <strong>(&gt;10,000 red blood cells (RBCs)/mm</strong><strong><sup>3</sup></strong><strong>)</strong> – Empiric parenteral antimicrobials  (<a class="graphic graphic_table graphicRef55679" href="/d/graphic/55679.html" rel="external">table 9</a>) and hospital observation.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>CSF not obtained (dry tap)</strong> – Hospital observation with or without empiric antibiotics.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lumbar puncture not performed</strong> – Hospital observation with or without empiric antibiotics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal urine studies </strong>– For patients with abnormal urine studies or one abnormal inflammatory marker (including a rectal temperature &gt;38.5°C [101.3°F] when procalcitonin measurement is not available), we suggest parenteral empiric antimicrobial treatment and hospital admission.</p><p></p><p class="bulletIndent1">The optimal management of febrile neonates whose preliminary urine studies suggest a UTI (eg, positive nitrites on dipstick, uncentrifuged sample with a positive Gram stain or &gt;10 white blood cells [WBCs]/mm<sup>3</sup>, or centrifuged sample with &gt;5 WBCs/high-power field) is unclear. We still suggest a full evaluation including collection of CSF studies, empiric antibiotics, and hospitalization. (See  <a class="medical medical_review" href="/d/html/5991.html" rel="external">"Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis", section on 'Parenteral antibiotics'</a>.)</p><p></p><p class="bulletIndent1">A prediction rule has been validated using data from over 1000 well-appearing febrile infants ≤90 days of age in Europe [<a href="#rid40">40</a>]. Well-appearing febrile infants ≤90 days of age at low risk for IBI were identified despite a positive urine dipstick based upon age &gt;15 days and normal procalcitonin (&lt;0.6 ng/mL) and C-reactive protein (&lt;20 mg/L) with a negative predictive value of 100 percent (95% CI 97.3-100 percent, IBI prevalence 4.9 percent). However, only a limited number of neonates 22 to 28 days of age were included in this analysis.</p><p></p><p>Based upon declines in sepsis and bacterial meningitis due to peri-partum GBS prophylaxis and the availability of more rapid blood culture results (typically within 24 to 36 hours), the 2021 AAP CPG offers the opportunity to do less evaluation and treatment in well-appearing, febrile neonates 22 to 28 days old [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H1722397610"><span class="h2">Viral infection</span></p><p class="headingAnchor" id="H3952490270"><span class="h3">Herpes simplex virus infection</span><span class="headingEndMark"> — </span>Febrile neonates with clinical suspicion for HSV infection  (<a class="graphic graphic_table graphicRef106132" href="/d/graphic/106132.html" rel="external">table 4</a>) should undergo a full sepsis evaluation, receive empiric <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a> and antibiotics, and be admitted to the hospital.</p><p>Appropriate testing for HSV should be obtained before the initiation of <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a>, whenever possible. Testing for and management of HSV infection in neonates are discussed separately. (See  <a class="medical medical_review" href="/d/html/6037.html" rel="external">"Neonatal herpes simplex virus infection: Clinical features and diagnosis", section on 'Detection of HSV'</a> and  <a class="medical medical_review" href="/d/html/6040.html" rel="external">"Neonatal herpes simplex virus infection: Management and prevention"</a>.)</p><p class="headingAnchor" id="H1955990621"><span class="h3">Other viral infections</span><span class="headingEndMark"> — </span>Neonates 7 to 28 days of age with diagnosed viral infections still have a significant risk for IBI (bacteremia or meningitis) and warrant treatment as if the viral infection is not present. (See <a class="local">'8 to 21 days old'</a> above and <a class="local">'22 to 28 days old'</a> above.)</p><p class="headingAnchor" id="H2701201722"><span class="h1">DISCHARGE CRITERIA FOR ADMITTED PATIENTS</span><span class="headingEndMark"> — </span>Admitted<strong> </strong>neonates (0 to 28 days of age) should receive inpatient care and parenteral antibiotics until all cultures are negative for at least 48 hours. Furthermore, initial treatment with <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a> implies significant clinical concern for herpes simplex virus (HSV) infection, and acyclovir should be continued until the results of <strong>all</strong> HSV testing are negative. (See  <a class="medical medical_review" href="/d/html/6037.html" rel="external">"Neonatal herpes simplex virus infection: Clinical features and diagnosis", section on 'Detection of HSV'</a> and  <a class="medical medical_review" href="/d/html/6040.html" rel="external">"Neonatal herpes simplex virus infection: Management and prevention", section on 'Initial antiviral therapy'</a>.)</p><p></p><p class="headingAnchor" id="H367495551"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111946.html" rel="external">"Society guideline links: Febrile young infants (younger than 90 days of age)"</a>.)</p><p class="headingAnchor" id="H1361322272"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/119058.html" rel="external">"Patient education: Fever in babies younger than 3 months (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/1177.html" rel="external">"Patient education: Fever in children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2622866338"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever definition</strong> – A rectal temperature ≥38°C (100.4°F) defines a fever in neonates. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The febrile neonate has an elevated risk for invasive bacterial infection (IBI; bacteremia and/or meningitis) or herpes simplex virus [HSV] infection. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stabilization</strong> – Unstable febrile neonates require rapid identification and treatment for septic shock  (<a class="graphic graphic_algorithm graphicRef128375" href="/d/graphic/128375.html" rel="external">algorithm 1</a>). (See <a class="local">'Stabilization'</a> above.)</p><p></p><p class="bulletIndent2">The evaluation should also identify and treat other causes of ill appearance in young infants as discussed separately. (See  <a class="medical medical_review" href="/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History</strong> – History should focus on risk factors for IBI  (<a class="graphic graphic_table graphicRef134341" href="/d/graphic/134341.html" rel="external">table 1</a>) and subtle findings of illness (eg, poor feeding, lethargy, or decreased activity). (See <a class="local">'History'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Physical examination</strong> – Physical examination focuses on general appearance and signs of (see <a class="local">'Physical examination'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Focal bacterial infection</p><p class="bulletIndent3"><span class="glyph">-</span>HSV infection</p><p class="bulletIndent3"><span class="glyph">-</span>Bronchiolitis</p><p></p><p class="bulletIndent2">Well appearance does <strong>not</strong> exclude the possibility of IBI. (See <a class="local">'Appearance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ancillary studies</strong> – The risk of IBI guides further evaluation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Higher IBI risk</strong> –<strong> </strong>For all febrile neonates 8 to 21 days old, we recommend a full sepsis evaluation  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a> and <a class="graphic graphic_algorithm graphicRef132304" href="/d/graphic/132304.html" rel="external">algorithm 2</a>) (see <a class="local">'Ancillary studies'</a> above); the evaluation of inpatient neonates &lt;8 days of age is discussed separately. (See  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a>.)</p><p></p><p class="bulletIndent2">For febrile neonates 22 to 28 days old, we recommend a full sepsis evaluation in patients with:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Ill appearance (see <a class="local">'Ill-appearing'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Focal bacterial infection (see <a class="local">'Focal infection'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Risk factors for IBI  (<a class="graphic graphic_table graphicRef106132" href="/d/graphic/106132.html" rel="external">table 4</a>) (see <a class="local">'22 to 28 days old'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lower IBI risk</strong> – For low-risk, well-appearing, febrile neonates 22 to 28 days old with a rectal temperature ≤38.5°C, we suggest a full sepsis evaluation. The decision to perform a lumbar puncture should be made as a shared decision between the clinician and family with a mutual understanding of the risks and benefits and with consideration of the family's values and preferences. (See <a class="local">'22 to 28 days old'</a> above.)</p><p></p><p class="bulletIndent2">A stepwise evaluation  (<a class="graphic graphic_table graphicRef134365" href="/d/graphic/134365.html" rel="external">table 7</a>) is also an acceptable option with cerebrospinal fluid (CSF) testing only in patients with  (<a class="graphic graphic_algorithm graphicRef132303" href="/d/graphic/132303.html" rel="external">algorithm 3</a>) (see <a class="local">'22 to 28 days old'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Temperature &gt;38.5°C (101.3°F) <strong>or</strong></p><p class="bulletIndent3"><span class="glyph">-</span>One or more abnormal blood inflammatory markers  (<a class="graphic graphic_table graphicRef134333" href="/d/graphic/134333.html" rel="external">table 8</a>)</p><p></p><p class="bulletIndent2">If preliminary urine studies are abnormal, we suggest obtaining CSF studies regardless of inflammatory marker results; other experts only perform a lumbar puncture when one or more inflammatory markers are also abnormal. (See <a class="local">'22 to 28 days old'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Viral infection</strong> – For febrile neonates diagnosed with a viral infection, we recommend a full sepsis evaluation  (<a class="graphic graphic_table graphicRef134330" href="/d/graphic/134330.html" rel="external">table 3</a>) for infants ≤21 days old and suggest it for infants 22 to 28 days old. All neonates with clinical features of HSV infection also require testing for HSV  (<a class="graphic graphic_table graphicRef106132" href="/d/graphic/106132.html" rel="external">table 4</a>). (See <a class="local">'Diagnosed with viral infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Admitted patients should receive care in units with nurses and ancillary staff experienced in the care of neonates:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ill-appearing</strong> – Ill-appearing febrile neonates require treatment for sepsis and septic shock  (<a class="graphic graphic_algorithm graphicRef128375" href="/d/graphic/128375.html" rel="external">algorithm 1</a>) in an intensive care unit. (See  <a class="medical medical_review" href="/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Empiric regimens'</a> and  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates", section on 'Admitted from the community'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Focal bacterial infections (pneumonia, skin, breast, bone, or joint)</strong> – Febrile neonates with focal infections should receive empiric parenteral antimicrobial therapy appropriate to provide broad coverage of the specific infection and undergo hospital admission. (See <a class="local">'Focal infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Well-appearing</strong> – The management of well-appearing neonates varies by age:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Neonates ≤21 days old</strong> – For well-appearing, febrile neonates ≤21 days old, we recommend empiric parenteral antimicrobial therapy  (<a class="graphic graphic_table graphicRef55679" href="/d/graphic/55679.html" rel="external">table 9</a>) and hospital admission  (<a class="graphic graphic_algorithm graphicRef132304" href="/d/graphic/132304.html" rel="external">algorithm 2</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'8 to 21 days old'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Neonates 22 to 28 days old</strong> – For well-appearing, febrile neonates 22 to 28 days old, we suggest empiric parenteral antimicrobial therapy and hospital admission pending culture results for all patients (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, for patients with normal blood inflammatory markers, initial urine testing, and (if obtained) CSF studies, alternative approaches as suggested by expert guidelines  (<a class="graphic graphic_algorithm graphicRef132303" href="/d/graphic/132303.html" rel="external">algorithm 3</a>) are reasonable alternatives. (See <a class="local">'Neonates 22 to 28 days old'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Viral infection</strong> – Febrile neonates with clinical suspicion for HSV infection should receive empiric <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a> in addition to antibiotics and undergo hospital admission as discussed separately. (See  <a class="medical medical_review" href="/d/html/6040.html" rel="external">"Neonatal herpes simplex virus infection: Management and prevention"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Neonates 7 to 28 days of age diagnosed with other viral infections still have a significant risk for IBI and warrant treatment as if the viral infection is not present. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Neonates with influenza warrant antiviral therapy, as discussed separately. (See  <a class="medical medical_review" href="/d/html/5985.html" rel="external">"Seasonal influenza in children: Management"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Antiviral and other therapies for coronavirus disease 2019 (COVID-19) in pediatric patients are discussed separately. (See  <a class="medical medical_review" href="/d/html/128389.html" rel="external">"COVID-19: Management in children"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sarna M, Ware RS, Lambert SB, et al. Timing of First Respiratory Virus Detections in Infants: A Community-Based Birth Cohort Study. J Infect Dis 2018; 217:418.</a></li><li><a class="nounderline abstract_t">Caviness AC, Demmler GJ, Almendarez Y, Selwyn BJ. The prevalence of neonatal herpes simplex virus infection compared with serious bacterial illness in hospitalized neonates. J Pediatr 2008; 153:164.</a></li><li><a class="nounderline abstract_t">Byington CL, Enriquez FR, Hoff C, et al. Serious bacterial infections in febrile infants 1 to 90 days old with and without viral infections. Pediatrics 2004; 113:1662.</a></li><li><a class="nounderline abstract_t">Blaschke AJ, Korgenski EK, Wilkes J, et al. Rhinovirus in Febrile Infants and Risk of Bacterial Infection. Pediatrics 2018; 141.</a></li><li class="breakAll">Hui C, Neto G, Tsertsvadze A, et al. Diagnosis and Management of Febrile Infants (0-3 months). Evidence Report/Technology Assessment No. 205 (Prepared by the University of Ottawa: Evidence-based Practice Center under Contract No. HHSA 290-2007-10059-I). AHRQ Publication No. 12-E004-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2012. Available at http://www.ahrq.gov/research/findings/evidence-based-reports/febrinftp.html (Accessed August 3, 2015)</li><li><a class="nounderline abstract_t">Maniaci V, Dauber A, Weiss S, et al. Procalcitonin in young febrile infants for the detection of serious bacterial infections. Pediatrics 2008; 122:701.</a></li><li><a class="nounderline abstract_t">Kadish HA, Loveridge B, Tobey J, et al. Applying outpatient protocols in febrile infants 1-28 days of age: can the threshold be lowered? Clin Pediatr (Phila) 2000; 39:81.</a></li><li><a class="nounderline abstract_t">Baker MD, Bell LM. Unpredictability of serious bacterial illness in febrile infants from birth to 1 month of age. Arch Pediatr Adolesc Med 1999; 153:508.</a></li><li><a class="nounderline abstract_t">Bachur RG, Harper MB. Predictive model for serious bacterial infections among infants younger than 3 months of age. Pediatrics 2001; 108:311.</a></li><li><a class="nounderline abstract_t">Garcia S, Mintegi S, Gomez B, et al. Is 15 days an appropriate cut-off age for considering serious bacterial infection in the management of febrile infants? Pediatr Infect Dis J 2012; 31:455.</a></li><li><a class="nounderline abstract_t">Pantell RH, Roberts KB, Adams WG, et al. Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Pantell RH, Newman TB, Bernzweig J, et al. Management and outcomes of care of fever in early infancy. JAMA 2004; 291:1203.</a></li><li><a class="nounderline abstract_t">Baraff LJ, Bass JW, Fleisher GR, et al. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med 1993; 22:1198.</a></li><li><a class="nounderline abstract_t">Gomez B, Mintegi S, Bressan S, et al. Validation of the "Step-by-Step" Approach in the Management of Young Febrile Infants. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Powell EC, Mahajan PV, Roosevelt G, et al. Epidemiology of Bacteremia in Febrile Infants Aged 60 Days and Younger. Ann Emerg Med 2018; 71:211.</a></li><li><a class="nounderline abstract_t">Sadow KB, Derr R, Teach SJ. Bacterial infections in infants 60 days and younger: epidemiology, resistance, and implications for treatment. Arch Pediatr Adolesc Med 1999; 153:611.</a></li><li><a class="nounderline abstract_t">Cruz AT, Mahajan P, Bonsu BK, et al. Accuracy of Complete Blood Cell Counts to Identify Febrile Infants 60 Days or Younger With Invasive Bacterial Infections. JAMA Pediatr 2017; 171:e172927.</a></li><li><a class="nounderline abstract_t">Mah V, Vanderkooi OG, Johnson DW. Epidemiology of Serious Bacterial Infections in Infants Less Than 90 Days of Age, Presenting to a Tertiary Care Emergency Department, 2010 to 2016. Pediatr Infect Dis J 2019; 38:e161.</a></li><li><a class="nounderline abstract_t">Byington CL, Rittichier KK, Bassett KE, et al. Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens. Pediatrics 2003; 111:964.</a></li><li><a class="nounderline abstract_t">Greenhow TL, Hung YY, Herz AM. Changing epidemiology of bacteremia in infants aged 1 week to 3 months. Pediatrics 2012; 129:e590.</a></li><li><a class="nounderline abstract_t">Leazer R, Perkins AM, Shomaker K, Fine B. A Meta-analysis of the Rates of Listeria monocytogenes and Enterococcus in Febrile Infants. Hosp Pediatr 2016; 6:187.</a></li><li><a class="nounderline abstract_t">Wittler RR, Bass JW. Nontyphoidal Salmonella enteric infections and bacteremia. Pediatr Infect Dis J 1989; 8:364.</a></li><li><a class="nounderline abstract_t">Torrey S, Fleisher G, Jaffe D. Incidence of Salmonella bacteremia in infants with Salmonella gastroenteritis. J Pediatr 1986; 108:718.</a></li><li><a class="nounderline abstract_t">Baker MD, Avner JR, Bell LM. Failure of infant observation scales in detecting serious illness in febrile, 4- to 8-week-old infants. Pediatrics 1990; 85:1040.</a></li><li><a class="nounderline abstract_t">Nigrovic LE, Mahajan PV, Blumberg SM, et al. The Yale Observation Scale Score and the rish of serious bacterial infection sin febrile infants. Pediatrics 2017; 140:e20170695.</a></li><li><a class="nounderline abstract_t">Bonadio WA, Hennes H, Smith D, et al. Reliability of observation variables in distinguishing infectious outcome of febrile young infants. Pediatr Infect Dis J 1993; 12:111.</a></li><li><a class="nounderline abstract_t">McLaren SH, Cruz AT, Yen K, et al. Invasive Bacterial Infections in Afebrile Infants Diagnosed With Acute Otitis Media. Pediatrics 2021; 147.</a></li><li><a class="nounderline abstract_t">Levine DA, Platt SL, Dayan PS, et al. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. Pediatrics 2004; 113:1728.</a></li><li><a class="nounderline abstract_t">Yarden-Bilavsky H, Ashkenazi-Hoffnung L, Livni G, et al. Month-by-month age analysis of the risk for serious bacterial infections in febrile infants with bronchiolitis. Clin Pediatr (Phila) 2011; 50:1052.</a></li><li><a class="nounderline abstract_t">Bonadio W, Huang F, Nateson S, et al. Meta-analysis to Determine Risk for Serious Bacterial Infection in Febrile Outpatient Neonates With RSV Infection. Pediatr Emerg Care 2016; 32:286.</a></li><li><a class="nounderline abstract_t">Payson A, Etinger V, Napky P, et al. Risk of Serious Bacterial Infections in Young Febrile Infants With COVID-19. Pediatr Emerg Care 2021; 37:232.</a></li><li><a class="nounderline abstract_t">Greenhow TL, Hung YY, Pantell RH. Management and Outcomes of Previously Healthy, Full-Term, Febrile Infants Ages 7 to 90 Days. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Nijman RG, Moll HA, Smit FJ, et al. C-reactive protein, procalcitonin and the lab-score for detecting serious bacterial infections in febrile children at the emergency department: a prospective observational study. Pediatr Infect Dis J 2014; 33:e273.</a></li><li><a class="nounderline abstract_t">Mintegi S, Bressan S, Gomez B, et al. Accuracy of a sequential approach to identify young febrile infants at low risk for invasive bacterial infection. Emerg Med J 2014; 31:e19.</a></li><li><a class="nounderline abstract_t">Blaschke AJ, Korgenski EK, Byington CL. Meninigitis in well-appearing febrile infants aged 1-90 days. Open Forum Infect Dis 2018; 5:S133.</a></li><li><a class="nounderline abstract_t">Wallace SS, Brown DN, Cruz AT. Prevalence of Concomitant Acute Bacterial Meningitis in Neonates with Febrile Urinary Tract Infection: A Retrospective Cross-Sectional Study. J Pediatr 2017; 184:199.</a></li><li><a class="nounderline abstract_t">Tebruegge M, Pantazidou A, Clifford V, et al. The age-related risk of co-existing meningitis in children with urinary tract infection. PLoS One 2011; 6:e26576.</a></li><li><a class="nounderline abstract_t">Mahajan P, VanBuren JM, Tzimenatos L, et al. Serious Bacterial Infections in Young Febrile Infants With Positive Urinalysis Results. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Velasco R, Benito H, Mozún R, et al. Febrile young infants with altered urinalysis at low risk for invasive bacterial infection. a Spanish Pediatric Emergency Research Network's Study. Pediatr Infect Dis J 2015; 34:17.</a></li><li><a class="nounderline abstract_t">Velasco R, Lejarzegi A, Gomez B, et al. Febrile young infants with abnormal urine dipstick at low risk of invasive bacterial infection. Arch Dis Child 2020.</a></li><li><a class="nounderline abstract_t">Gómez B, Mintegi S, Benito J, et al. Blood culture and bacteremia predictors in infants less than three months of age with fever without source. Pediatr Infect Dis J 2010; 29:43.</a></li><li><a class="nounderline abstract_t">Bizzarro MJ, Raskind C, Baltimore RS, Gallagher PG. Seventy-five years of neonatal sepsis at Yale: 1928-2003. Pediatrics 2005; 116:595.</a></li><li><a class="nounderline abstract_t">Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 2020; 395:200.</a></li><li><a class="nounderline abstract_t">Martinez E, Mintegi S, Vilar B, et al. Prevalence and predictors of bacterial meningitis in young infants with fever without a source. Pediatr Infect Dis J 2015; 34:494.</a></li><li><a class="nounderline abstract_t">Mintegi S, Gomez B, Martinez-Virumbrales L, et al. Outpatient management of selected young febrile infants without antibiotics. Arch Dis Child 2017; 102:244.</a></li></ol></div><div id="topicVersionRevision">Topic 134347 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29165576" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Timing of First Respiratory Virus Detections in Infants: A Community-Based Birth Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18534225" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The prevalence of neonatal herpes simplex virus infection compared with serious bacterial illness in hospitalized neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173488" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Serious bacterial infections in febrile infants 1 to 90 days old with and without viral infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29343585" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rhinovirus in Febrile Infants and Risk of Bacterial Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29343585" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Rhinovirus in Febrile Infants and Risk of Bacterial Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18829791" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Procalcitonin in young febrile infants for the detection of serious bacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10696544" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Applying outpatient protocols in febrile infants 1-28 days of age: can the threshold be lowered?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10323632" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Unpredictability of serious bacterial illness in febrile infants from birth to 1 month of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11483793" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Predictive model for serious bacterial infections among infants younger than 3 months of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22209915" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Is 15 days an appropriate cut-off age for considering serious bacterial infection in the management of febrile infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34281996" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15010441" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management and outcomes of care of fever in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8517575" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27382134" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Validation of the "Step-by-Step" Approach in the Management of Young Febrile Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28988964" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Epidemiology of Bacteremia in Febrile Infants Aged 60 Days and Younger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10357302" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bacterial infections in infants 60 days and younger: epidemiology, resistance, and implications for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28892537" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Accuracy of Complete Blood Cell Counts to Identify Febrile Infants 60 Days or Younger With Invasive Bacterial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30408003" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Epidemiology of Serious Bacterial Infections in Infants Less Than 90 Days of Age, Presenting to a Tertiary Care Emergency Department, 2010 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12728072" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22371459" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Changing epidemiology of bacteremia in infants aged 1 week to 3 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980752" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A Meta-analysis of the Rates of Listeria monocytogenes and Enterococcus in Febrile Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2664692" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nontyphoidal Salmonella enteric infections and bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3701519" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence of Salmonella bacteremia in infants with Salmonella gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2339027" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Failure of infant observation scales in detecting serious illness in febrile, 4- to 8-week-old infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Yale Observation Scale Score and the rish of serious bacterial infection sin febrile infants</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8426766" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Reliability of observation variables in distinguishing infectious outcome of febrile young infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33288730" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Invasive Bacterial Infections in Afebrile Infants Diagnosed With Acute Otitis Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173498" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21685212" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Month-by-month age analysis of the risk for serious bacterial infections in febrile infants with bronchiolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27139289" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Meta-analysis to Determine Risk for Serious Bacterial Infection in Febrile Outpatient Neonates With RSV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33780408" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk of Serious Bacterial Infections in Young Febrile Infants With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940667" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Management and Outcomes of Previously Healthy, Full-Term, Febrile Infants Ages 7 to 90 Days.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25093971" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : C-reactive protein, procalcitonin and the lab-score for detecting serious bacterial infections in febrile children at the emergency department: a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23851127" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Accuracy of a sequential approach to identify young febrile infants at low risk for invasive bacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Meninigitis in well-appearing febrile infants aged 1-90 days</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28185626" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prevalence of Concomitant Acute Bacterial Meningitis in Neonates with Febrile Urinary Tract Infection: A Retrospective Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22096488" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The age-related risk of co-existing meningitis in children with urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36097858" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Serious Bacterial Infections in Young Febrile Infants With Positive Urinalysis Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25036049" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Febrile young infants with altered urinalysis at low risk for invasive bacterial infection. a Spanish Pediatric Emergency Research Network's Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33246922" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Febrile young infants with abnormal urine dipstick at low risk of invasive bacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19934784" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Blood culture and bacteremia predictors in infants less than three months of age with fever without source.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16140698" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Seventy-five years of neonatal sepsis at Yale: 1928-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31954465" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25461476" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prevalence and predictors of bacterial meningitis in young infants with fever without a source.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470162" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Outpatient management of selected young febrile infants without antibiotics.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
